Listing of Claims:

The listing of claims presented below reflects the pending claims in the instant application as of the mailing date of the non-final Office Action (*i.e.*, February 26, 2008). No amendments have been made herein to the pending claims, and this listing of claims has been provided solely for the Examiner' s convenience:

1. (Previously Presented) A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurolidine or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.

2. - 4. (Cancelled)

5. (Previously Presented) The method of claim 1, wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.

6. (Previously Presented) The method of claim 1, wherein said composition is administered by intraperitoneal lavage.

7. (Previously Presented) The method of claim 1, wherein said composition is administered systematically.

8. (Previously Presented) The method of claim 7, wherein said composition is administered intravenously.

9. (Cancelled)

10. (Original) The method of claim 1, wherein said composition comprises taurolidine.

11. (Original) The method of claim 1, wherein said composition comprises a taurolidine derivative or metabolite.

12. (Original) The method of claim 1, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

13. (Previously Presented) A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurultam or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.

14. - 16. (Cancelled)

17. (Previously Presented) The method of claim 13, wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.

18. (Previously Presented) The method of claim 13, wherein said composition is administered by intraperitoneal lavage.

19. (Previously Presented) The method of claim 13, wherein said composition is administered systematically.

20. (Previously Presented) The method of claim 19, wherein said composition is administered intravenously.

21. (Cancelled)

22. (Original) The method of claim 13, wherein said composition comprises taurultam.

23. (Original) The method of claim 13, wherein said composition comprises a taurultam derivative or metabolite.

24. (Original) The method of claim 13, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

25. - 77. (Cancelled)

78. (Previously Presented) The method of claim 1, wherein said composition consists of taurolidine and a pharmaceutically acceptable excipient.

79. (Previously Presented) The method of claim 1, wherein said composition consists of taurolidine, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.

80. (Previously Presented) The method of claim 79, wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

81. (Previously Presented) The method of claim 13, wherein said composition consists of taurultam and a pharmaceutically acceptable excipient.

82. (Previously Presented) The method of claim 1, wherein said taurolidine is administered prophylactically at the time of surgery of said primary tumor.

83. (Previously Presented) The method of claim 13, wherein said composition consists of taurultam, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.

84. (Previously Presented) The method of claim 83, wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

85. (Previously Presented) The method of claim 13, wherein said taurultam is administered prophylactically at the time of surgery of said primary tumor.